1338367-30-8Relevant academic research and scientific papers
Selective sodium channel regulator as well as preparation and application thereof
-
, (2021/02/10)
The invention provides a compound serving as a selective sodium channel regulator and a synthesis and use method, and particularly provides a compound shown as a formula (I), a preparation method of the compound and application of the compound serving as the selective sodium channel regulator. The compounds exhibit excellent activity as a regulator of sodium channels.
MODULATORS OF POTASSIUM ION AND TRPV1 CHANNELS AND USES THEREOF
-
, (2019/05/02)
Novel compounds usable in modulating an activity or function of a voltage-dependent potassium channel and/or of TRPV1 are provided. The compounds are represented by Formula I as described and defined in the specification.
RORGAMMA MODULATORS AND USES THEREOF
-
, (2018/08/20)
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
-
, (2014/07/08)
The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
Design and synthesis of new prostaglandin D2 receptor antagonists
Iwahashi, Maki,Takahashi, Eiji,Tanaka, Motoyuki,Matsunaga, Yoko,Okada, Yutaka,Matsumoto, Ryoji,Nambu, Fumio,Nakai, Hisao,Toda, Masaaki
experimental part, p. 5361 - 5371 (2011/10/12)
To identify new cost-effective prostaglandin D2 (DP) receptor antagonists, a series of novel 3-benzoylaminophenylacetic acids were synthesized and biologically evaluated. Among those tested, some representative compounds were found to be orally
